VIKING THERAPEUT.DL -,005 WKN: A12GD6 ISIN: US92686J1060 Kürzel: VKTX Forum: Aktien Thema: Hauptdiskussion

On November 3, Viking Therapeutics is making headlines due to its recent clinical trial updates and strong financial standing, enabling it to advance development of its key weight-loss drug, VK2735. This investigational therapy, a GLP-1/GIP receptor agonist, showed promising results in its Phase 2 VENTURE trial, demonstrating an average body weight reduction of 9.1% to 14.7% over a 13-week period, depending on dosage. Encouraged by these results, Viking received FDA feedback, allowing the company to accelerate planning for Phase 3 trials, expected to involve over 4,500 participants and to cost roughly $300 million【5†source】【6†source】. Viking is also working on an oral form of VK2735 and has a pipeline that includes other metabolic therapies, such as VK2809, aimed at treating metabolic-associated fatty liver disease, and VK0214, targeting X-linked adrenoleukodystrophy. Viking’s strategic plan for VK2735 includes potentially offering both weekly and monthly injection options, alongside an oral tablet, to provide flexibility and meet varied patient needs. This proactive approach aligns Viking as a potential competitor with larger pharmaceutical players in the obesity space【5†source】.